Colorectal Cancers in China
Conditions
Interventions
Gold Standard:Pathological diagnosis
screening 
model 
of 
cancer
Sponsors
Changhai Hospital, the Second Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) fully understand the study and sign informed consent voluntarily; (2) aged 35-75 years, male and female; (3) patients with pathologically confirmed advanced colorectal adenoma, stage I or II colorectal cancer who are initially treated with surgery.
Exclusion criteria
Exclusion criteria: (1) have a history of other gastrointestinal tumors or inflammatory bowel diseases (possibly influenced by bacterial infection); (2) have undergone resection of colorectal adenoma or have a family history of colorectal cancer, known as HNPCC (hereditary non-polyposis colorectal cancer);Autosomal dominant inheritance), FAP (familial adenomatous polyposis;Often; (3) received allogeneic blood transfusion, transplantation and allogeneic cell therapy within 1 month; (4) received antibiotic treatment within 3 months; (5) known HIV or hepatitis b virus carrier; (6) colorectal surgery; (7) other concurrent cancers; (8) participated in an interventional clinical trial within 30 days; (9) took probiotic drugs within 3 months; (10) long-term use of laxatives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensibility;Specificity;Positive Predictive Value;Negative Predictive Value;Tissue Biomarker Methylation;Tissue Biomarker Mutation;Blood Biomarker Methylation;Stool Mutation;Stool Methylation;Stool Bacteria; | — |
Countries
China
Contacts
Public ContactZhaoshen Li
Changhai Hospital, the Second Military Medical University
Outcome results
None listed